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Sprouty (Spry) proteins are negative regulators of receptor tyrosine kinase signaling; however, their exact mechanism of
action remains incompletely understood. We identiﬁed phosphatidylinositol-speciﬁc phospholipase C (PLC)- as a
partner of the Spry1 and Spry2 proteins. Spry–PLC interaction was dependent on the Src homology 2 domain of PLC
and a conserved N-terminal tyrosine residue in Spry1 and Spry2. Overexpression of Spry1 and Spry2 was associated with
decreased PLC phosphorylation and decreased PLC activity as measured by production of inositol (1,4,5)-triphosphate
(IP3) and diacylglycerol, whereas cells deﬁcient for Spry1 or Spry1, -2, and -4 showed increased production of IP3 at
baseline and further increased in response to growth factor signals. Overexpression of Spry 1 or Spry2 or small-interfering
RNA-mediated knockdown of PLC1o rP L C 2 abrogated the activity of a calcium-dependent reporter gene, suggesting
that Spry inhibited calcium-mediated signaling downstream of PLC. Furthermore, Spry overexpression in T-cells, which
are highly dependent on PLC activity and calcium signaling, blocked T-cell receptor-mediated calcium release. Accord-
ingly, cultured T-cells from Spry1 gene knockout mice showed increased proliferation in response to T-cell receptor
stimulation. These data highlight an important action of Spry, which may allow these proteins to inﬂuence signaling
through multiple receptors.
INTRODUCTION
Cell proliferation and fate are in large part controlled
through the actions of receptor tyrosine kinases (RTKs).
Ligation of such receptors by their cognate ligands activates
several intracellular signaling pathways, including the Ras/
mitogen-activated protein (MAP) kinase (MAPK)-, the phos-
phatidyl inositol/AKT-, and phosphatidylinositol-speciﬁc
phospholipase C (PLC)-mediated pathways (Fantl et al.,
1993; Schlessinger, 2000). The extent of RTK activation is
dependent on factors such as the concentration and avail-
ability of ligand and the number of receptors on the cell
surface. In addition, many negative regulatory mechanisms
have evolved to limit signaling by RTKs. These mechanisms
include the degradation of receptors through the action of
c-Cbl and related ubiquitin ligases, the induction of inhibi-
tory membrane-associated molecules such as SEF (Similar
expression to FGF gene), and the secretion of proteins that
sequester ligand as in the Drosophila protein Argos (Ledda
and Paratcha, 2007). The sprouty gene was ﬁrst identiﬁed as
an antagonist of tracheal branching in the ﬂy (Hacohen et al.,
1998) and subsequently was shown to be a general inhibitor
of RTKs (Casci et al., 1999; Kramer et al., 1999; Reich et al.,
1999). There are four Spry genes in higher vertebrates with
only partial overlap in expression pattern (Minowada et al.,
1999) and some distinct biochemical properties (Mason et al.,
2006; Edwin et al., 2009). Sprouty genes are induced in
response to RTK signaling through both MAP kinase (Ozaki
et al., 2001) and calcium signaling pathways (Abe and Naski,
2004), and vertebrate Spry proteins were shown to consis-
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3487tently antagonize signaling through the ﬁbroblast growth
factor (FGF), platelet-derived growth factor (PDGF), glial
cell-derived neurotrophic factor (GDNF), and vascular en-
dothelial growth factor (VEGF) receptors (Mason et al., 2006;
Cabrita and Christofori, 2008). Targeted deletion of Spry
genes in mice yields defects in the development of many
organs, including kidney, cochlea, and tooth due to exces-
sive signaling through speciﬁc RTKs, which can be rescued
by genetic reduction of RTK signaling (Basson et al., 2005,
2006; Shim et al., 2005; Klein et al., 2006, 2008). The molecular
mechanism by which Spry proteins inhibit RTK signaling
remains uncertain. Spry proteins can interact with multiple
components of the Ras/MAPK pathway, including Grb2
(Hanafusa et al., 2002; Tefft et al., 2002), FRS2 (Tefft et al.,
2002), Shp2 (Tefft et al., 2002), c-Cbl (Wong et al., 2001; Fong
et al., 2003; Hall et al., 2003; Rubin et al., 2003; Mason et al.,
2004), Raf1 (Tefft et al., 2002; Sasaki et al., 2003), and GAP1
(Tefft et al., 2002). These interactions only partially explain
the ability of Spry proteins to inhibit Ras and MAP kinase
activation.
The two isoforms of PLC, PLC1 and PLC2, are both
activated by phosphorylation through growth factor recep-
tor tyrosine kinases as well as nonreceptor tyrosine kinases
(Wells et al., 2003). PLC2 is primarily expressed in cells of
hematopoietic lineage, whereas PLC1 is ubiquitously ex-
pressed (Wilde and Watson, 2001). Although PLC1 is crit-
ical for many cells, it is the predominant isoform in T-cells,
whereas PLC2 is important in B-cells, mast cells, and plate-
lets (Kurosaki et al., 2000). PLC1 has an essential role in
mammalian development because mice deﬁcient for PLC1
die by embryonic day 9 (Ji et al., 1998). The PLC2 gene
knockout showed restricted growth and abnormalities in B-,
mast, and natural killer cells and a block in crystallizable
fragment receptor (FcR)-mediated responses (Wang et al.,
2000). PLC1 is among the signaling molecules that bind to
the intracellular domain of activated growth factor recep-
tors. Subsequent tyrosine phosphorylation of PLC1 leads to
increased enzymatic activity (Peters et al., 1992; Ronnstrand
et al., 1992; Rotin et al., 1992; Middlemas et al., 1994). Acti-
vated PLC1 hydrolyzes phosphatidylinositol-4,5-bisphos-
phate (PIP2) into inositol (1,4,5)-triphosphate (IP3) and diac-
ylglycerol (DAG), which are important second messengers
(Rhee, 2001). IP3 binds to a receptor on the endoplasmic
reticulum, causing the release of Ca2 into the cytosol,
whereas DAG recruits protein kinase C (PKC) isoforms to
plasma membranes and facilitates its activation and engage-
ment in signaling. Both the increase of Ca2 levels and
activation of PKC are important for cell differentiation, pro-
liferation, and growth (Hardingham and Bading, 1999; Oliva
et al., 2005). PLC-mediated increase of DAG can lead to
activation of speciﬁc Ras-guanine nucleotide exchange fac-
tors and stimulation of the MAP kinase pathway (Bivona et
al., 2003). Furthermore, calcium-stimulated activation of
PKC can lead to the phosphorylation and activation of c-Raf
in a Ras-independent manner (Marais et al., 1998).
To clarify mechanisms by which Spry regulates signaling
networks, we searched for proteins that interact with Spry
that may mediate its ability to inhibit signal transduction.
We identiﬁed PLC as a protein that interacts with Spry1
and -2, particularly after growth factor stimulation of cells.
Here, we showed that overexpression of Spry1 and Spry2
was associated with decreased PLC activity as measured
by the production of IP3 or DAG after receptor stimulation.
Deletion of Spry genes in murine embryonic ﬁbroblasts or
mast cells was associated with increased PLC activity.
These ﬁndings highlight another important function of
Spry proteins and indicate their ability to regulate several
branches of signaling downstream of multiple cell surface
receptors.
MATERIALS AND METHODS
Cell Lines
NIH 3T3 cells inducible for expression of murine Spry1 (NIH 3T3-Spry1) or
Spry2 (NIH 3T3-Spry2) were created by stable transfection of NIH-3T3 cells
with Spry1 inserted into pBIG2i (Strathdee et al., 1999). Spry1ﬂox/ﬂox (Basson
et al., 2005), Spry2ﬂox/ﬂox (Shim et al., 2005), and Spry4ﬂox/ﬂox (Klein et al.,
2006) mice were interbred to create mice homozygous for all three alleles.
Fibroblasts created from these mouse embryos were immortalized by passage
under a 3T3 protocol and infected with recombinant adenoviruses AdCMV5-
eGFP or AdCMVCre-eGFP (Gene Transfer Vector Core, University of Iowa,
Iowa City, IA) to delete the Sprouty alleles. Mast cells were created from
Spry2 gene knockout mice (Basson et al., 2005; Shim et al., 2005) by culturing
bone marrow cells for 4 wk in Iscove’s modiﬁed Dulbecco media  glutamine
containing 10 ng/ml interleukin (IL)-3 and 20 ng/ml murine stem cell factor
(SCF). Spry1,2,4ﬂox/ﬂox ﬁbroblasts treated with adenovirus vector or adeno-
virus-expressed Cre vector and Spry2 wt and Spry2 null mast cells were
genotyped to conﬁrm the deletion of respective Spry genes. Genotyping
polymerase chain reaction primers and conditions are indicated in Supple-
mental Data.
Immunoblot and Immunoprecipitation Analysis
The following antibodies were used for the study: phospho-42/44 MAP
kinase, phospho-AKT, phospho-Raf (Cell Signaling Technology); FLAG (Sigma-
Aldrich, St. Louis, MO); hemagglutinin (HA; Roche Diagnostics, Indianapolis,
IN); PLC1, PLC2, PLC1, PLC1 (Santa Cruz Biotechnology, Santa Cruz,
CA); and phospho-PLC1 and phospho-PLC2 (Cell Signaling Technology).
Rabbit polyclonal sera against Spry1 and Spry2 were described previously
(Gross et al., 2001). Immunoprecipitations and immunoblots were performed
after transient transfection of 293T cells as described previously (Mason et al.,
2004). The immunoblots were visualized by the enhanced chemiluminescence
detection system (GE Healthcare, Little Chalfont, Buckinghamshire, United
Kingdom).
Luciferase Assay
NIH 3T3 cells engineered to express Spry1 under doxycycline control were
plated 24 h before transfection in DMEM with 10% serum. The cells were
transiently cotransfected in duplicate with nuclear factor of activated T-cells
(NFAT) luciferase reporter (5 g) and Renilla (50 ng) plasmids by using
FuGENE Transfection Reagent (GE Healthcare). Serum-starved (0.2% serum-
containing media  doxycycline) cells were left unstimulated or stimulated
with either basic (b)FGF (20 ng/ml) or PDGF BB (20 ng/ml) for 4 h. The cells
were then assayed using the Dual-Luciferase Assay kit (Promega, Madison,
WI), normalizing ﬁreﬂy luciferase activity to Renilla luciferase activity. For
assessing luciferase activity with Spry2, the Spry1-inducible NIH 3T3 cells
were transiently cotransfected in duplicate with an NFAT luciferase reporter
(5 g), Renilla (50 ng), and Spry2 (1 g) expression plasmids by using
FuGENE Transfection Reagent (GE Healthcare). The medium was replaced
with starvation medium (0.2% serum-containing media, without doxycycline)
for 24 h after transfection. Cells were either left unstimulated or stimulated
with bFGF (20 ng/ml) or PDGF BB (20 ng/ml) for 4 h. Equal quantities of cell
lysate were then assayed using the Dual-Luciferase Assay kit (Promega),
normalizing luciferase activity to Renilla luciferase activity.
Small-interfering RNA (siRNA)-mediated PLC1 and
PLC2 Knockdown
siGENOME SMARTpool duplex RNA oligonucleotides targeting mouse
PLC1 and PLC2 or scrambled control siRNA were purchased from Dhar-
macon RNA Technologies (Lafayette, CO). NIH 3T3 cells were treated with
indicated siRNA by using HiPerFect (QIAGEN, Valencia, CA) for 24 h fol-
lowed by transfections with the indicated plasmids. Cells were analyzed for
the luciferase activity or PLC1 and PLC2 protein levels by immunoblot as
described above.
Calcium Mobilization Assay
Jurkat T-cells (2  106) were transfected with 1 g of enhanced green ﬂuo-
rescent protein (EGFP) and 3 g of Spry1 or empty vector with DMRIE-C
transfection reagent (Invitrogen, Carlsbad, CA). After 24 h, the cells were
incubated with 5 M indo-1-acetoxymethyl ester (indo-1; Invitrogen) in RPMI
1640 medium (Invitrogen) at 37°C for 30 min. The cells were then washed and
resuspended in minimal essential medium without phenol red. Cells were
incubated at 37°C for 5 min before ﬂow cytometry measurements were taken.
Baselines were acquired, and anti-CD3 antibody was added (3 g/ml) after 1
min. Data were collected for another 4 min. Calcium levels were plotted as a
ratio between calcium-bound indo-1 and unbound indo-1 versus time. The
data were analyzed using FlowJo software (Tree Star, Ashland, OR).
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Fibroblasts were seeded in a 10-cm dish with DMEM containing 10% fetal
bovine serum (FBS). After 20 h, cells were serum starved (0.2% FBS) with
fresh medium containing 2 Ci/ml myo-[3H]inositol (PerkinElmer Life and
Analytical Sciences, Boston, MA) and incubated overnight. Cells were washed
twice and preincubated for1hi nmedia containing 20 mM LiCl and 1 mg/ml
bovine serum albumin (BSA), followed by stimulation with PDGF BB (20
ng/ml) for the indicated time. Mast cells were seeded in Iscove’s modiﬁed
Dulbecco media  glutamine containing 10 ng/ml IL-3 and 20 ng/ml murine
SCF for overnight incubation. Cells were serum starved (0.2% FBS) with fresh
medium containing 2 Ci/ml myo-[3H]inositol (PerkinElmer Life and Ana-
lytical Sciences) plus immunoglobulin (Ig)E anti-2,4-dinitrophenyl (DNP) and
incubated overnight. The cells were washed twice and preincubated for 1 h in
media containing 20 mM LiCl and 1 mg/ml BSA, followed by stimulation
with DNP-BSA. After treatment with PDGF or anti-DNP, stimulation media
were removed from the cells, and 2 ml of ice-cold 0.4 M HClO4 was added to
the cells for 5 min. The samples were then neutralized with 2 ml of 0.72 M
KOH  0.6 M KHCO3, and the precipitate was removed by centrifugation.
The resulting supernatant was applied to an ion exchange column (AGI-X8,
catalog no. 143-2445; Bio-Rad Laboratories, Hercules, CA) and sequentially
eluted with 0.2, 0.6, and 1.2 M ammonium formate/0.1 M formic acid to
isolate inositol monophosphate (IP1), inositol diphosphate (IP2), and IP3,
respectively. Radioactivity in the fractions was measured by scintillation
counting (LS-6500 counter; Beckman Coulter, Fullerton, CA; Paris and Pouys-
segur, 1987) and normalized to total radioactivity incorporation in each
experiment.
DAG Signaling and Confocal Microscopy
RBL-2H3, a rat mast cell line, was cultured in DMEM containing 10% FBS and
transfected with plasmids encoding green ﬂuorescent protein (GFP)-tagged
Cys-domains of PKC (Oancea et al., 1998) and DsRed Spry2 by using Superfect
(QIAGEN). Cells were plated on glass-bottomed dishes (MatTek, Ashland,
MA), and the next day the media were changed to extracellular buffer (5 mM
KCl, 125 mM NaCl, 20 mM HEPES, pH 7.4, 1.5 mM CaCl2, 1.5 mM MgCl2, and
10 mM glucose). Cell stimulation via the FcR1 was carried out by incubation
with 1 g/ml IgE anti-DNP (Sigma-Aldrich) for 8 h, followed by antigenic
cross-linking of bound IgE by using 20 g/ml DNP-BSA (Invitrogen). Fluo-
rescence confocal microscopy (model LSM 510 Meta; Carl Zeiss, Jena, Ger-
many) was used to monitor the translocation of the GFP-fusion construct in
response to stimulus. Timed series of images were recorded before and after
stimulation of cells, and midsections of the cells are shown in all the images.
T-Cell Isolation
T-cells were isolated from Spry1/, Spry1/, and Spry1/ mice by dis-
aggregation of lymph nodes into air-buffered media containing 1% FBS,
washed, counted, and resuspended in complete RPMI 1640 medium (10%
FBS, glutamine, and Pen/Strep). Total lymph node cells (5  105/well) were
cultured in round-bottomed 96-well plates and stimulated in triplicate wells
with soluble anti-CD3 (145-2C11 at the indicated concentrations) in combina-
tion with anti-CD28 (1 g/ml) antibodies for 72 h. Cultures were pulsed with
0.5 Ci of [3H]thymidine in the last 18 h of culture, harvested, and counted in
a beta counter with scintillation.
Flow Cytometry
Jurkat T-cells (2  106) were transfected with 1 g of EGFP and 3 g of Spry1
or Spry2 or empty vector with DMRIE-C transfection reagent (Invitrogen).
After 48 h, cells were stimulated with 3 g/ml anti-CD3 antibody (R&D
Systems, Minneapolis, MN) for 16 h. Cells were then washed and suspended
in 300 l of media with 25 l of phycoerythrin-conjugated anti-human CD69
antibody (BD Biosciences Pharmingen, San Diego, CA) for 30 min in the dark.
CD69 expression was analyzed by ﬂow cytometry (FACscan; BD Biosciences,
San Jose, CA) after gating on GFP-positive cells.
RESULTS
PLC1 and PLC2 Associate with Spry1 and Spry2
A search of the Alliance for Cell Signaling database (Saun-
ders et al., 2008) of a large-scale yeast two-hybrid screen
indicated interaction between Sprouty2 and PLC2. To con-
ﬁrm this interaction, human embryonic kidney (HEK)293
cells were transiently cotransfected with plasmids encoding
epitope-tagged Spry1, Spry2, PLC1, and PLC2. PLC1
(Figure 1A) and PLC2 (Figure 1B) were readily coprecipi-
tated with Spry1 or Spry2. Interaction between endogenous
Figure 1. PLC1 and PLC2 coimmunoprecipi-
tate with Spry1 and Spry2. (A) HEK293 cells were
transfected with plasmids expressing epitope-
tagged Spry and PLC as indicated. Spry1 and
Spry2 were immunoprecipitated with anti-Spry1
or anti-Spry2 antibody. HA-PLC1 was immuno-
precipitated (lane 4) with anti-HA antibody. The
immunoprecipitates were probed with anti-HA an-
tibody to detect coimmunoprecipitated PLC1 (top)
and with anti-FLAG antibody to detect Spry1 and
Spry2 (bottom). (B) HEK293 cells were cotransfected
with cDNAs encoding FLAG-tagged Spry1 or
FLAG-tagged Spry2 and PLC2 as indicated. After
48 h, lysates were prepared, and immunoprecipita-
tions were performed using speciﬁc anti-Spry1 or
anti-Spry2 antibody (left). Total cell lysate (50 g)
was resolved in 10% SDS-polyacrylamide gel electro-
phoresis gel and probed with anti-PLC2 and anti-
FLAG antibodies to show the expression level of the
transfectants (right). (C) mIMCD3 cells growing in
media containing 10% FBS were lysed and subjected
to immunoprecipitation with anti-Spry1 and anti-
PLC1 antibodies or IgG or anti histone H3 controls,
followed by immunoblotting with anti-Spry1 or
PLC1. (D) Murine IMCD3 cells were serum starved
for 18 h followed by HGF (40 ng/ml) stimulation for
the indicated time. Endogenous Spry1 and PLC1
interaction was demonstrated by immunoprecipita-
tion with anti-Spry1 antibody and immunoblotting
for PLC1. Total cell lysate was blotted with PLC1
to show the endogenous level of PLC1 in the cell
lysates after stimulation with HGF. Bottom, lysate
from a second experiment was immunoblotted for
activated phosphorylated (p)-ERK and total ERK to
show the time course of activation of signaling in
response to HGF.
Sprouty Inhibits PLC
Vol. 21, October 1, 2010 3489Spry1 and PLC1 was detected in murine IMCD3 cells that
express high levels of Spry1 (Basson et al., 2006; Figure 1C,
lane 2). In IMCD3 cells starved for growth factor, the Spry1–
PLC1 interaction was minimal (Figure 1D, lane 1), but after
stimulation with hepatocyte growth factor (HGF), which
stimulates extracellular signal-regulated kinase (ERK) activ-
ity in these cells (Figure 1D, bottom), the interaction was
readily detected, reaching a maximum after 30 min (Figure
1D). The inducible nature of the Spry1–PLC1 interaction
also was reconstructed in an FGF-dependent system in
HEK293 cells, by using epitope-tagged Spry1 and PLC
(data not shown).
Given the presence of Src homology 2 (SH2) domains in
PLC and that Spry proteins can bind to c-Cbl and other
SH2 domain-containing proteins, a glutathione transferase
(GST) fusion protein consisting of the C-terminal SH2 do-
main of PLC (Reddi et al., 2007) was produced in Escherichia
coli (Supplemental Figure 1) and incubated with cell lysate
isolated from 293T cells transfected with either wild-type
Spry1, Spry2, or versions of the Spry proteins in which
conserved N-terminal tyrosine residues located within an
SH2 binding domain were mutated (Y53A and Y55A, re-
spectively; Mason et al., 2004). Immunoblot analysis showed
almost equal expression of wild-type and mutant forms of
Spry1 and Spry2 (Figure 2A). GST-PLC1-SH2-C was bound
to wild-type but not with the tyrosine mutant forms of Spry
(Figure 2B). Curiously, Spry1 or Spry2 derived from extracts
of serum-starved cells could still bind to the GST-PLC1
protein. This could denote the presence of residual tyrosine
phosphorylated Spry in the cell extracts even after serum
starvation. Accordingly, a small amount of Spry–PLC1 in-
teraction was detected by coprecipitation of extracts of se-
rum-starved cells (Figure 1D, t  0). After growth factor
stimulation, PLC1 and PLC2 bind to growth factor recep-
tors through an SH2 domain and become phosphorylated
(Carpenter and Ji, 1999). To determine the consequences of
the Spry1–PLC1 interaction, we measured the activation
state of PLC as marked by Y783 phosphorylation. As we
reported previously, a doxycycline-responsive system for
the conditional expression of Spry1 strongly inhibited MAP
kinase activation after growth factor stimulation (Figure 2;
Gross et al., 2001; Mason et al., 2004). In the absence of
doxycycline, PDGF rapidly stimulated PLC1 and PLC2
tyrosine phosphorylation (Figure 2D, left). However, in the
presence of Spry1, PLC1 and PLC2 phosphorylation was
inhibited 33–60%, depending on the time after stimulation
(Figure 2D, right). As reported previously, expression of
PLC1 and PLC1 was almost undetectable in these cells
(Supplemental Figure 2; Smith et al., 1990); hence, it is un-
likely that Spry1 or Spry2 affects signaling through these
other members of the PLC family in ﬁbroblasts. Collectively,
these data demonstrate that Spry interacts with the PLC
protein, and this is associated with decreased phosphoryla-
tion and presumably activation of this enzyme.
Sprouty Inhibits IP3 Production, Calcium Release, and
Calcium-dependent Transcription
Having shown that Spry1 and Spry2 interact with PLC1
and PLC2, we asked whether signals downstream of PLC
were affected by Spry. PLC catalyzes the breakdown of
PIP2 into DAG and IP3. We measured directly the effect of
Spry expression on inositol phosphate production in several
systems. In NIH 3T3 cells treated with PDGF, there was a
time-dependent increase in the concentration of IP3 as well
as the IP3 metabolites IP2 and IP1 that result from the action
of phosphatases on IP3. When Spry1 expression was induced
(Supplemental Figure 3A) in these cells, abrogation of IP3
and IP3 metabolite production in response to PDGF was
observed (Figure 3A and Supplemental Table 1A). As a
complimentary experiment, we measured inositol phos-
phate production in a murine embryo ﬁbroblasts (MEFs)
loss-of-function system in which LoxP site-ﬂanked Spry1, -2,
and -4 alleles were all excised by infection with adenovirus-
Cre. Spry1,2,4 null ﬁbroblasts (Supplemental Figure 3, B and
D) had elevated basal levels of IP1,I P 2, and IP3 after serum
starvation compared with MEFs infected with adenovirus-
GFP (Figure 3B and Supplemental Table 1B). Stimulation of
these cells with PDGF led to a further increase in inositol
phosphate production. To determine whether elimination of
Figure 2. Sprouty–PLC1 interaction requires an N-ter-
minal conserved tyrosine residue of Sprouty. (A) 293T
cells were transfected with either wild type or mutant
Spry1 or Spry 2 as indicated. Thirty-six hours after trans-
fection, cells were starved with 0.2% serum-containing
medium for 12 h, and cells were stimulated with indicated
growth factors for 10 min. Aliquots (50 g) of whole cell
lysate from unstimulated or stimulated cells were sub-
jected to immunoblotting with anti-FLAG antibody to vi-
sualize Spry1 (top) and Spry2 (bottom) expression. (B)
293T cells were transfected with FLAG-tagged wild-type
(WT) Spry1 or Spry2 or N-terminal tyrosine mutants as
indicated. The cells were starved with 0.2% FBS-contain-
ing medium for 12 h and were stimulated with indicated
growth factors for 10 min. The cell lysates from stimulated
or unstimulated cells were incubated with 20 g of GST or
GST-PLC1-SH2-C fusion proteins. The GST-bound pro-
teins were eluted in SDS loading buffer, and the bound
Spry was detected by immunoblotting with anti-FLAG
antibody. (C) Spry1 expression in a stable 3T3 cell line was
induced by addition of doxycycline to starvation media
containing 0.2% FBS and then stimulated with PDGF BB
(20 ng/ml) for 15 min. Cell lysates were probed for total
and phospho-ERK. (D) 3T3 cells were stimulated for in-
creasing periods of time with PDGF BB (20 ng/ml) in the
presence or absence of doxycycline (Dox) to induce Spry1
expression. Cell lysates were immunoblotted for total and
phosphorylated PLC1 and PLC2 as indicated.
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production, we studied mast cells derived from Spry2 null
mice (Supplemental Figure 3C). Fc receptor stimulation ac-
tivates PLC1 and PLC2 in mast cells (Barker et al., 1998). In
response to Fc receptor stimulation, Spry2/ mast cells
showed increased production of IP3 and metabolites com-
pared with cultured cells from Spry2/ replete littermate
controls (Figure 3C and Supplemental Table 1C). Similar
levels of Fc receptor in cell surface were measured in
Spry2/ and Spry2/ mast cells (data not shown). Col-
lectively, these data indicate that Spry proteins regulate IP3
production in the cell, consistent with the inhibition of PLC
activity.
IP3 normally stimulates release of Ca2 from intracellular
stores by binding to speciﬁc channel/receptor on the endo-
plasmic reticulum (Foskett et al., 2007). To directly assess the
ability of Spry to affect calcium release, we used Jurkat
T-cells, which express PLC1. T-cell receptor (TCR)-medi-
ated signaling and activation of MAP kinase is highly de-
pendent on PLC in these cells (Bivona et al., 2003; Perez de
Castro et al., 2004). Jurkat cells transfected with Spry1 or
Spry2 along with GFP or with GFP alone were loaded with
the calcium-sensitive dye indo-1 and stimulated with anti-
CD3 antibody. Changes in intracellular calcium levels over
time were monitored by ﬂow cytometry, gating GFP-posi-
tive cells. TCR engagement with anti-CD3 antibody induced
a rapid increase in calcium concentration in the control
Jurkat cells, peaking at 200 s after stimulation. In cells trans-
fected with Spry1 or Spry2, calcium mobilization was
strongly suppressed (Figure 4A). These data suggest that
Spry1 and Spry2 prevent the coupling of TCR signaling to
PLC1 activation and Ca2 mobilization in Jurkat T-cells.
To determine whether Spry led to changes in calcium-
mediated signaling, we measured the transcriptional activ-
ity of the NFAT transcription factor, which is regulated by
the calcium-sensitive phosphatase calcineurin (Feske et al.,
2001). NIH 3T3 ﬁbroblasts engineered to conditionally ex-
press Spry1 were transfected with a reporter gene harboring
a NFAT binding site along with Renilla luciferase internal
control. This reporter was robustly induced by the addition
of PDGF or FGF. When Spry1 was induced by doxycycline
addition, the reporter gene activity was severely reduced,
and no induction in response to FGF or PDGF was noted.
Similarly when these cells were transiently transfected with
a Spry2 expression vector, the activity of the NFAT lucif-
erase reporter was inhibited (Figure 4B), suggesting that
Spry inhibited the PLC-generated calcium signals down-
stream of these growth factors. Accordingly, siRNA-medi-
ated depletion of endogenous PLC1o rP L C 2 (Supplemen-
tal Figure 4, A and B) blocked PDGF-mediated activation of
the reporter gene to a similar extent as overexpression of
Spry1 or Spry2 (Figure 4C). The combination of knockdown
of PLC and overexpression of Spry1 or Spry2 also showed
complete inhibition of NFAT reporter activity (Supplemen-
tal Figure 4C, top and bottom). These data suggest that
PLC1 and PLC2 act together to stimulate calcium release
in the cell, and overexpression of Spry phenocopies the loss
of function of one of these proteins, consistent with the
notion that Spry1 and Spry2 interfere with PLC function.
To determine the biological signiﬁcance of the effect of
Spry on T-cell receptor signaling that largely depends on
calcium release, T-cells were isolated from Spry1 null ani-
mals and treated with graded doses of anti-CD3 antibody.
Proliferation was measured by incorporation of [3H]thymi-
dine. As seen in Figure 4D, T-cells from Spry1/ mice
showed increased proliferation at every dose of agonistic
anti-CD3 antibody. Similarly, T-cells from mice homozy-
gous for a LoxP-ﬂanked Spry1 allele (Basson et al., 2005,
2006) and deleted for Spry1 by crossing with CD4-Cre mice
showed increased proliferation in response to CD3 ligation
(data not shown).
Spry Modulates the Production of Diacylglycerol
To further demonstrate the ability of Spry to inhibit PLC
activity, we determined the ability of Spry to affect produc-
tion of DAG, the other product of PLC-mediated hydroly-
sis of PIP2, by using an assay that reﬂects the cell biological
effects of DAG. When DAG is generated at the plasma
membrane regions, it recruits signaling proteins such as
PKC isoforms. A fusion protein consisting of the C1 domain
of PKC protein fused to GFP binds DAG and translocates
from cytosol to the plasma membrane after IgE (FcRI)
Figure 3. Spry inhibits inositol phosphate
(IP) production after receptor stimulation. (A)
NIH 3T3 cells cultured in the presence of [3H]in-
ositol were serum starved and stimulated with
PDGF BB (20 ng/ml) for increasing periods in
the presence or absence of doxycycline (Dox)
to induce Spry1 expression. Lipids were col-
lected from the cell lysates, and radiolabeled IPs
were fractionated and counted by liquid scintil-
lation. Inositol phosphate levels are expressed as
a percentage of total radioactive inositol incor-
poration. (B) Spry1,2,4 null or control adenovi-
rus-GFP ﬁbroblasts were serum starved and
treated with PDGF BB (20 ng/ml) for the indi-
cated times and assayed for IPs. (C) A bone
marrow mast cell line derived from a wild-type
or Spry2/ mouse was treated with IgE fol-
lowed by dinitrophenol-human serum albumin
to cross-link Fc receptors. Cell lysates were pre-
pared at the indicated times and assayed for IPs.
All experiments were performed three times (see
Supplemental Table 1, A–C) with similar results
obtained.
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1998). The PKC-C1-GFP construct was transfected into this
mast cell line with or without DsRed Spry2, and in more
than a dozen individual cells both conditions were analyzed
by live-cell confocal microscopy, with images taken at 10-s
intervals after IgE receptor stimulation. Examination of a
representative cell transfected with the GFP reporter protein
alone showed that before Fc cross-linking, PKC-C1-GFP
was homogenously distributed across the cytosol and the
nucleus (Figure 5Aa). After addition of DNP-bovine serum
albumin to cross-link DNP-speciﬁc IgE-primed Fc receptors,
PKC-C1-GFP rapidly relocalized to the plasma membrane
(Figure 5A, compare a and a, arrows). By contrast, when
mast cells were transfected with Spry2, the redistribution of
PKC-C1-GFP to the plasma membrane was prevented (Fig-
ure 5A, b and b). DsRed-tagged Spry2 itself was localized at
the plasma membrane in unstimulated as well as cross-
linked cells (Figure 5A, c and c). Analysis of multiple indi-
vidual cells by time course microscopy showed that expres-
sion of Spry2 almost always (11/13 cells tested) inhibited the
translocation of the PKC probe (Table 1). By contrast, most
cells (12/16) stimulated by Fc cross-linking but not trans-
fected with Spry2 showed migration of the probe to the
plasma membrane. When phorbol 12-myristate 13-acetate
(PMA), a mimic of DAG, was applied to mast cells express-
ing DsRed Spry2, PKC-C1-GFP readily relocated to the
plasma membrane (Figure 5B). This showed that the ability
of Spry2 to localize at the plasma membrane by itself did not
block the ability of PKC-C1-GFP to accumulate at the
plasma membrane. Collectively, these data suggest that Spry
expression inhibits the generation of DAG in the cell and not
the DAG-dependent translocation of PKC to the mem-
brane, a ﬁnding consistent with the ability of Spry to inhibit
PLC activity.
Increased PLC activity leads to the recruitment of protein
kinase C molecules, including PKC, to the plasma mem-
brane (Griner and Kazanietz, 2007), and DAG-mediated al-
losteric changes in PKC cooperate with the action of the
serine-threonine kinase PDK1 to phosphorylate and activate
the kinase (Le Good et al., 1998). Accordingly, overexpres-
sion of Spry1 in NIH 3T3 cells was associated with decreased
phosphorylation of PKC on threonine 505, a modiﬁcation
associated with activation of the enzyme (Figure 5C). By
contrast in Spry1,2,4 knockout MEFs, PKC phosphorylation
was increased after growth factor receptor activation com-
pared with control MEFs (Figure 5D). Collectively, these
data indicate that Spry modulates the activity of PLC and
downstream pathways, including the activity of PKC.
Spry Suppresses CD69, a T-Cell Marker for Activation of
the Ras/MAPK Pathway
Activation of the Ras/MAP kinase pathway by TCR stimu-
lation leads to the up-regulation of cell surface activation
markers such as CD69 (Testi et al., 1994). Previous work
indicated that TCR-mediated activation of Ras/MAP kinase
was highly dependent on PLC1 activity and activation of a
Figure 4. Sprouty inhibits intracellular cal-
cium mobilization and signaling in T-cells and
ﬁbroblasts. (A) Jurkat T-cells were cotrans-
fected with a GFP expression vector (1 g)
along with either empty pcDNA (3 g) or
Spry1 or Spry2 expression vector (3 g) as in-
dicated. The cells were then loaded with indo-1
and after baseline measurements of 60 s and
stimulated with anti-CD3 (3 mg/ml) antibody.
Measurements were taken for up to 300 s. In-
tracellular calcium mobilization was analyzed
by ﬂuorescence-activated cell sorting analysis
by monitoring the ﬂuorescence emission ratio
of the indo-1 bound to Ca2 versus the free
form at 405 and 495 nM, respectively. The ex-
periment was performed three times with sim-
ilar results obtained. (B) Spry1-inducible NIH
3T3 cells were transiently cotransfected with a
reporter containing an NFAT-responsive ele-
ment (5 g) and Renilla (50 ng), starved for 24 h
in media containing 0.2% FBS, and stimulated
either with bFGF (20 ng/ml; top) or PDGF BB
(20 ng/ml; bottom) for 4h. Spry1 was induced
by doxycycline addition to the starvation me-
dia; Spry2 was expressed by transient transfec-
tion of a Spry2 expression plasmid in cells cul-
tured in the absence of doxycycline. After
growth factor addition, equal quantities of cell
extracts (50 g) were assayed using the Dual-
Luciferase Assay kit (Promega), normalizing
luciferase activity to Renilla luciferase activity.
The experiments were repeated three times,
and similar results were obtained. Luc, lucif-
erase. (C) NIH 3T3 cells were treated with si-
GENOME SMARTpool directed against PLC1
or PLC2 for 24 h followed by transient trans-
fection with NFAT luciferase reporter (5 g)
and Renilla (50 ng) plasmids by using FuGENE Transfection Reagent (GE Healthcare) in duplicate. Serum-starved (0.2% FBS-containing
serum media) cells were either left unstimulated or stimulated with PDGF BB (20 ng/ml) for 4 h. Luciferase activity was assayed as described
above. (D) T-cells from Spry1/ mice were cultured in triplicate with the indicated amount of anti-CD3 antibody in combination with
anti-CD28 (1 g/ml) antibody for 72 h, and [3H]thymidine incorporation was quantiﬁed by liquid scintillation counting.
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were transfected with a GFP expression vector alone or with
a Spry1 or Spry2 expression vector and were left untreated
or treated with anti-CD3. In response to CD3 stimulation,
GFP-transfected cells showed a threefold increase in CD69
expression (Figure 6A). In accordance with its ability to
inhibit PLC activity, overexpression of Spry1 (Figure 6B) or
Spry2 (Figure 6C) in Jurkat T-cells robustly blunted the
induction of CD69 after CD3 stimulation. These results show
that Spry1 and Spry 2 inhibit TCR-mediated activation of the
Ras/MAPK pathway.
DISCUSSION
The Spry proteins seem to limit signaling through interac-
tions with several partner proteins. We identiﬁed an inter-
action between Spry proteins and PLC that further charac-
terizes the inhibitory action of the Spry proteins on signaling
downstream of many different receptor tyrosine kinases,
including the FGF receptor, PDGF receptor, T-cell receptor,
and Fc receptor. Calcium signaling pathways as well as the
Ras/MAP kinase pathway stimulate Spry expression, pre-
sumably as part of a negative feedback loop. Speciﬁcally,
Spry1 and Spry2 expression can be induced by FGF through
calcium-dependent pathways. Mutant forms of the FGF re-
ceptor 3 receptor were unable to bind and activate PLC1.
They only weakly induced Spry1 and Spry2 in contrast to
the robust induction by wild-type receptor (Abe and Naski,
2004). Signaling through phosphotidyinositol hydrolysis
also affects the localization of Spry. Spry2 in particular was
shown to bind to PIP2, which may attract Spry to the plasma
membrane rufﬂes after active signaling, allowing it to fur-
ther limit signaling (Lim et al., 2002).
In this work, we showed that Spry1 and Spry2 directly
interacts with PLC and affects the PLC-mediated signal-
ing. Spry overexpression was associated with decreased
PLC phosphorylation and decreased PLC activity as
shown by decreased IP3 generation, calcium release, and
DAG production. Cells deleted for one or multiple Spry
genes showed increased IP3 production in response to
growth factor receptor activation. There have been previous
indications that Spry may affect signaling through the PLC
pathway. Nutt et al. (2001) showed that in Xenopus oocytes,
overexpression of Xenopus Spry2 (Xspry2) inhibited Ca2
signaling but failed to affect MAP kinase signaling. In con-
trast, in the same system Drosophila sprouty inhibited MAP
kinase but not Ca2 signaling. Another report using Xspry2
showed inhibition of Ca2 signaling and PKC activity,
whereas Xspred proteins inhibited MAP kinase signaling
(Sivak et al., 2005). These studies suggested that Spry pro-
teins inhibited either Ca2 signaling via the PLC pathway
or MAPK signaling through Ras but not both the signaling
pathways in the same system. Our data indicate that murine
Figure 5. Spry2 prevents relocalization of a DAG re-
porter protein to the plasma membrane and inhibits
signaling downstream of DAG. (A) Fluorescent images
of RBL-2H3 mast cells transfected with a DAG binding
reporter protein construct (PKC-C1-GFP) without (a
and a) or with (b and b) transfection of Spry2 before (a
and b) and after (a and b) cross-linking of the IgE
receptors with DNP-BSA. c and c show DsRed Spry2
expression in the mast cell presented in b and b. (B) The
mast cell from b and b was treated with PMA showing
membrane localization of DsRed Spry2 and PKC-C1-
GFP after stimulation. Sixteen vector-transfected cells
and 13 Spry2-transfected cells were analyzed as de-
scribed above with results presented in Table 1. (C) NIH
3T3 cells engineered to express Spry1 under doxycy-
cline control treated overnight with doxycycline in star-
vation media, treated with PDGF BB (20 ng/ml) for the
indicated times, and then cell lysates were immunoblot-
ted with antibodies directed against PKC and phos-
pho-threonine 505-modiﬁed PKC. (D) Sprouty1,2,4
null or control ﬁbroblasts were serum starved and
treated with PDGF BB (20 ng/ml) for the indicated
times. Cell lysates were immunoblotted for PKC and
phospho-threonine 505-PKC. WT, wild type.
Table 1. Localization of PKC-GFP probe after mast cell stimulation
Probe at membrane Probe in cytoplasm
Vector 12 4
Spry2* 2 11
*p 0.005 by chi-square.
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MAP kinase. This may explain the ability of Spry to affect
signaling downstream of a diverse set of receptors. Further-
more, the ability of Spry to inhibit PLC-mediated signaling
may contribute to its ability to affect ERK activation. Inhibi-
tion of PLC activity can alter downstream signaling by
reducing DAG levels. Reduction in the DAG level limits the
activity of Ras-Grp1, a known guanine nucleotide exchange
factor involved in the conversion of inactive guanosine
diphosphate (GDP)-bound Ras to active guanosine triphos-
phate (GTP)-bound Ras (Roose et al., 2005). Decreased Ras-
Grp1 activity can lead to lower levels of active GTP-bound
Ras. In addition, DAG normally stimulates PKC isoforms
that phosphorylate and stimulate Raf (Schonwasser et al.,
1998); hence, decreased PLC activity in response to Spry
can in this way also leads to decreased ERK activity.
The inhibitory effect of the Spry1–PLC interaction also
was reﬂected by the reduced transcriptional activity of
NFAT. NFAT activity is modulated by cytoplasmic Ca2
concentration, which is increased by IP3-mediated release of
calcium from intracellular stores (Masuda et al., 1998;
Crabtree and Olson, 2002). Increases in cytoplasmic Ca2
concentration induce NFAT dephosphorylation and NFAT
translocation to the nucleus where it binds to cis-regulatory
elements of target genes. In accordance with our results,
Choi et al. (2006) also found that Spry1 overexpression in-
hibited NFAT activation, suggesting that Spry1 limited cal-
cium release after signaling. Lee et al. (2009) showed an
association of Spry1 overexpressed in T-cells with Linker for
activation of T cells (LAT), a tyrosine kinase linking the
T-cell receptor to downstream signaling, as well as PLC1.
In contrast to our results in ﬁbroblasts, this group found that
Spry1 overexpression decreased LAT but not PLC1 ty-
rosine phosphorylation. By contrast our gain-of-function
and loss-of-function studies link Spry1 and Spry2 to PLC
activity and downstream signaling. Spry may affect phos-
photodylinositol-mediated signaling by more than one
mechanism. One group found that that Spry4 inhibited
VEGF-stimulated PIP2 hydrolysis by PLC but not ERK
activation. This activity seemed to be related to the ability of
Spry4 to bind PIP2, perhaps sequestering this substrate from
PLC. Unlike our results with Spry1 and Spry2, Spry4 ex-
pression was not associated with decreased PLC phosphor-
ylation, and the interaction between Spry4 and PLC was
not explored (Ayada et al., 2009).
We showed previously by targeted deletion of the Spry1
gene that Spry1 speciﬁcally inhibited the action of GDNF via
the Ret receptor during kidney development (Basson et al.,
2005, 2006). A recent study showed that loss of Spry1 in mice
rescued renal agenesis resulting from a mutant allele of
Ret that could no longer directly activate Ras via Grb2 and
SOS but that could only signal through the PLC pathway
(Rozen et al., 2009). This observation is consistent with our
data and suggests that Spry1 inhibits PLC-mediated sig-
naling in vivo.
In IMCD3 cells, endogenous Spry1 interacted with PLC
modestly under serum starvation conditions and more ro-
bustly after growth factor stimulation, which leads to Spry
tyrosine phosphorylation (Gross et al., 2001). Interaction be-
tween the SH2 domain of PLC1 and Spry1 in vitro was
dependent, at least in part, on the conserved N-terminal Y53
residue of the protein (Y55 in Spry2). This N-terminal ty-
rosine residue is also critical for interaction of Spry with
proteins such as c-Cbl (Fong et al., 2003), Shp2 (Hanafusa et
al., 2004), and PP2A (Lao et al., 2007). The interplay between
Spry and c-Cbl can modulate epidermal growth factor re-
ceptor levels (Haglund et al., 2005), but c-Cbl is not required
for the inhibitory action of Spry on signaling (Mason et al.,
2004). Shp2 may dephosphorylate the N-terminal tyrosine
and inhibit Spry function (Hanafusa et al., 2004). PP2A bind-
ing through the N terminus is associated with serine–threo-
nine dephosphorylation of Spry2, which facilitates its ability
to bind Grb2, potentially interfering with the coupling of
receptor tyrosine kinases to Ras activation (Lao et al., 2007).
The interaction of Spry with PLC through its N-terminal
domain represents another way for Spry proteins to modu-
late signal transduction.
We found that Spry1- and Spry2-expressing cells inefﬁ-
ciently coupled TCR signaling to calcium mobilization. Fur-
thermore, CD69 expression, an indication of Ras/MAP ki-
nase activation in T-cells (Dumont et al., 1998) was inhibited
by enforced expression of Spry1 or Spry2. Conversely, loss
of Spry1 expression led to increased proliferation of T-cells
after stimulation of the T-cell receptor. Given that T-cells are
highly dependent on DAG-stimulated Ras-GRP to activate
Ras, this also suggests that Spry1 and Spry2 inhibited PLC
Figure 6. Spry suppresses induction of CD69,
an MAP-kinase dependent marker in T-cells.
Jurkat cells were transfected with GFP alone
(A), with GFP and Spry1 (B), or with GFP and
Spry2 (C) and left unstimulated or stimulated
for 16 h with anti-CD3; stained with phyco-
erythrin-conjugated anti-CD69 expression, and
analyzed by ﬂow cytometry. Histograms of cell
number versus ﬂuorescence intensity are plot-
ted, and mean ﬂuorescence intensity of each
curve is presented. The experiments were re-
peated three times, and similar results were ob-
tained.
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signaling (Choi et al., 2006), suggesting that, as in other
receptor-mediating signaling pathways, Spry proteins act as
part of a negative feedback loop to limit receptor mediated
signaling and to modulate immune responses. In support of
these results, Spry1 is up-regulated in anergic T-cells that fail
to proliferate in response to antigen (Powell, unpublished
data). T-cell anergy is characterized by diminished intercel-
lular Ca2 mobilization, in response to improper signaling
from the TCR (Macian et al., 2004). Spry, being a negative
regulator of calcium signaling, could help to enforce anergy.
Having no evident function as an enzyme, the role of Spry
proteins as regulators of signaling pathways remains to be
fully elucidated. Spry proteins interact with multiple signal-
ing molecules, including Grb2, Shp2, SIAH, PTP1B, caveo-
lin, TESK1, and Raf (Mason et al., 2006; Edwin et al., 2009).
The identiﬁcation of partner proteins has yielded important
insight into Spry function. Interplay between Spry and the
PLC represents one important mode of action of these
relatively small but complicated molecules in diverse cell
systems.
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